121 related articles for article (PubMed ID: 38175741)
1. Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases.
Martínez-Feito A; Novella-Navarro M; Hernández-Breijo B; Nozal P; Peiteado D; Villalba A; Nuño L; Monjo I; Pascual-Salcedo D; Balsa A; Plasencia-Rodríguez C
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38175741
[TBL] [Abstract][Full Text] [Related]
2. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution.
Vultaggio A; Nencini F; Carraresi A; Pratesi S; Movérare R; Eriksson C; Venemalm L; Maggi E; Matucci A
Allergy; 2018 Nov; 73(11):2172-2181. PubMed ID: 29719053
[TBL] [Abstract][Full Text] [Related]
3. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
[TBL] [Abstract][Full Text] [Related]
4. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
[TBL] [Abstract][Full Text] [Related]
5. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
[TBL] [Abstract][Full Text] [Related]
6. Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
Kharlamova N; Hermanrud C; Dunn N; Ryner M; Hambardzumyan K; Vivar Pomiano N; Marits P; Gjertsson I; Saevarsdottir S; Pullerits R; Fogdell-Hahn A
Front Immunol; 2020; 11():1365. PubMed ID: 32793189
[TBL] [Abstract][Full Text] [Related]
7. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
Nencini F; Vultaggio A; Pratesi S; Cammelli D; Milla M; Fiori G; Bagnoli S; Prignano F; Romagnani S; Maggi E; Matucci A
J Allergy Clin Immunol Pract; 2018; 6(6):2065-2072.e2. PubMed ID: 29660428
[TBL] [Abstract][Full Text] [Related]
8. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay.
Van Stappen T; Brouwers E; Vermeire S; Gils A
Drug Test Anal; 2017 Feb; 9(2):243-247. PubMed ID: 26990872
[TBL] [Abstract][Full Text] [Related]
9. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
Hock BD; McKenzie JL; Goddard L; Smith SM; McEntyre CJ; Keating PE
Ther Drug Monit; 2018 Dec; 40(6):705-715. PubMed ID: 30439789
[TBL] [Abstract][Full Text] [Related]
10. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.
Hambardzumyan K; Hermanrud C; Marits P; Vivar N; Ernestam S; Wallman JK; van Vollenhoven RF; Fogdell-Hahn A; Saevarsdottir S;
Scand J Rheumatol; 2019 Sep; 48(5):362-366. PubMed ID: 31244356
[No Abstract] [Full Text] [Related]
11. Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
Tournier Q; Paul S; Williet N; Berger AE; Veyrard P; Boschetti G; Le Roy B; Killian M; Phelip JM; Flourie B; Nancey S; Roblin X
Aliment Pharmacol Ther; 2021 Jun; 53(11):1190-1200. PubMed ID: 33872404
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
Siljehult F; Ärlestig L; Eriksson C; Rantapää-Dahlqvist S
Scand J Rheumatol; 2018 Sep; 47(5):345-350. PubMed ID: 29701536
[TBL] [Abstract][Full Text] [Related]
13. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
14. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
[TBL] [Abstract][Full Text] [Related]
17. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Vultaggio A; Petroni G; Pratesi S; Nencini F; Cammelli D; Milla M; Prignano F; Annese V; Romagnani S; Maggi E; Matucci A;
Clin Exp Immunol; 2016 Dec; 186(3):364-372. PubMed ID: 27569750
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
19. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
20. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]